Globotrioasylsphingosine Levels and Optical Coherence Tomography Angiography in Fabry Disease Patients.
fabry disease
globotrioasylsphingosine
lysosomal storage disorder
optical coherence tomography angiography
vessel density
vessel length density
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
05 Mar 2021
05 Mar 2021
Historique:
received:
27
01
2021
revised:
16
02
2021
accepted:
04
03
2021
entrez:
3
4
2021
pubmed:
4
4
2021
medline:
4
4
2021
Statut:
epublish
Résumé
To date, there are no studies associating the dried blood spot (DBS) levels of globotrioasylsphingosine (lysoGb3) with quantitative optical coherence tomography angiography (OCTA) parameters in Fabry disease (FD) patients. Here, we aimed to investigate the association between OCTA vessel density (VD), vessel length density (VLD) with DBS lysoGb3. A retrospective, single center analysis of all consecutive FD patients enrolled at the Department of Ophthalmology of the University Hospital of Zurich from 1 December 2017 to 9 September 2020. An association between VD and VLD detected by OCTA and lysoGb3 was investigated using a linear mixed model. A total of 57 FD patients (23 male, 34 female; 109 eyes) were included. Forty-one patients suffered from the classic phenotype and 16 from the later-onset phenotype. LysoGb3 inversely correlated with VD and VLD in both the superficial (VD: Our study shows an association between lysoGb3 and OCTA VD and VLD. This supports the hypothesis that quantitative OCTA parameters might be useful as diagnostic biomarkers for evaluating systemic involvement in FD, and possibly other diseases.
Sections du résumé
BACKGROUND
BACKGROUND
To date, there are no studies associating the dried blood spot (DBS) levels of globotrioasylsphingosine (lysoGb3) with quantitative optical coherence tomography angiography (OCTA) parameters in Fabry disease (FD) patients. Here, we aimed to investigate the association between OCTA vessel density (VD), vessel length density (VLD) with DBS lysoGb3.
METHODS
METHODS
A retrospective, single center analysis of all consecutive FD patients enrolled at the Department of Ophthalmology of the University Hospital of Zurich from 1 December 2017 to 9 September 2020. An association between VD and VLD detected by OCTA and lysoGb3 was investigated using a linear mixed model.
RESULTS
RESULTS
A total of 57 FD patients (23 male, 34 female; 109 eyes) were included. Forty-one patients suffered from the classic phenotype and 16 from the later-onset phenotype. LysoGb3 inversely correlated with VD and VLD in both the superficial (VD:
CONCLUSIONS
CONCLUSIONS
Our study shows an association between lysoGb3 and OCTA VD and VLD. This supports the hypothesis that quantitative OCTA parameters might be useful as diagnostic biomarkers for evaluating systemic involvement in FD, and possibly other diseases.
Identifiants
pubmed: 33807900
pii: jcm10051093
doi: 10.3390/jcm10051093
pmc: PMC7961664
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Novartis
ID : C11711734926
Références
Eur J Ophthalmol. 2021 Jan;31(1):158-165
pubmed: 31617414
Br J Ophthalmol. 2017 Sep;101(9):1193-1200
pubmed: 28057649
Clin Genet. 2016 Jan;89(1):44-54
pubmed: 25974833
J Clin Med. 2020 Jun 02;9(6):
pubmed: 32498362
J Clin Med. 2019 Apr 17;8(4):
pubmed: 30999633
Clin Chem. 2013 Mar;59(3):547-56
pubmed: 23237761
N Engl J Med. 2016 Aug 11;375(6):545-55
pubmed: 27509102
Expert Opin Biol Ther. 2004 Jul;4(7):1167-76
pubmed: 15268683
Invest Ophthalmol Vis Sci. 2019 Jun 3;60(7):2667-2675
pubmed: 31242288
Annu Rev Genomics Hum Genet. 2012;13:307-35
pubmed: 22970722
Proc Natl Acad Sci U S A. 2008 Feb 26;105(8):2812-7
pubmed: 18287059
Mutat Res Genet Toxicol Environ Mutagen. 2015 Jun;784-785:31-6
pubmed: 26046974
Int Ophthalmol. 2020 Nov;40(11):3023-3032
pubmed: 32607948
Int J Retina Vitreous. 2017 May 15;3:13
pubmed: 28515959
J Clin Med. 2020 Dec 18;9(12):
pubmed: 33352849
J Inherit Metab Dis. 2009 Dec;32 Suppl 1:S67-77
pubmed: 19259782
Contrib Nephrol. 2001;(136):174-92
pubmed: 11688379
Mol Biosyst. 2015 Jun;11(6):1543-51
pubmed: 25666440
J Am Soc Nephrol. 2018 Sep;29(9):2265-2278
pubmed: 30093456
PLoS One. 2020 Dec 8;15(12):e0243236
pubmed: 33290417
ESC Heart Fail. 2020 Jun;7(3):825-834
pubmed: 32100468
Acta Ophthalmol. 2019 Nov 26;:
pubmed: 31773840
BMJ Open Respir Res. 2018 Apr 21;5(1):e000277
pubmed: 29713479
JAMA. 2001 Jun 6;285(21):2743-9
pubmed: 11386930
Br J Ophthalmol. 2007 Feb;91(2):210-4
pubmed: 16973664
Lasers Med Sci. 2021 Jan 6;:
pubmed: 33409749
Ann Intern Med. 2003 Feb 18;138(4):338-46
pubmed: 12585833
Ophthalmologica. 1978;176(6):313-30
pubmed: 211468
Retina. 2017 Mar;37(3):592-603
pubmed: 28225726
Ophthalmology. 1991 May;98(5 Suppl):741-56
pubmed: 2062510
Int J Cardiol. 2017 Dec 15;249:261-267
pubmed: 28964554
J Hum Genet. 2016 Feb;61(2):143-9
pubmed: 26490183
Mol Genet Metab. 2018 Feb;123(2):148-153
pubmed: 28728877
Surv Ophthalmol. 2008 Jul-Aug;53(4):416-23
pubmed: 18572058
Acta Ophthalmol. 2013 Mar;91(2):e113-9
pubmed: 23164241
Acta Ophthalmol (Copenh). 1981 Oct;59(5):674-82
pubmed: 6797229
Mol Genet Metab Rep. 2019 Feb 06;19:100454
pubmed: 30775256
Ophthalmic Paediatr Genet. 1985 Apr;5(3):185-90
pubmed: 3934620
Orphanet J Rare Dis. 2013 Aug 06;8:116
pubmed: 23915644
Stroke. 2009 Mar;40(3):788-94
pubmed: 19150871
JAMA. 1999 Jan 20;281(3):249-54
pubmed: 9918480
J Inherit Metab Dis. 2020 Mar;43(2):326-333
pubmed: 31449323
Int J Mol Med. 2009 Sep;24(3):401-7
pubmed: 19639234
Mol Genet Metab. 2017 Jan - Feb;120(1-2):57-61
pubmed: 27773586
Curr Med Chem. 2018;25(13):1530-1537
pubmed: 28618999
Prog Retin Eye Res. 2018 May;64:1-55
pubmed: 29229445
Mol Genet Metab. 2017 Aug;121(4):320-324
pubmed: 28663131
Biochim Biophys Acta. 2012 Feb;1822(2):226-32
pubmed: 22085605
J Med Genet. 2015 May;52(5):353-8
pubmed: 25795794
J Ophthalmol. 2020 Sep 21;2020:2650873
pubmed: 33029387
Acta Diabetol. 2017 Jul;54(7):695-702
pubmed: 28474119
JAMA Ophthalmol. 2015 Jan;133(1):45-50
pubmed: 25317632